Trailing-twelve-month (TTM) revenue is $2.16 Billion with a year-over-year growth of (8.98%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $536,990,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $540,310,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-19 |
| Q1 FY2026Period ended 2026-03-31 | $530,374,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $551,683,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $2,159,357,000 |
Current P/S: $3,957,234,313 market capitalization ÷ $2,159,357,000 TTM revenue = 1.83x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T15:10:11.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $551.68M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:12:33.823Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Critical Care | $49M | $49M | $47M | N/A | N/A | N/A |
| Equipment revenue | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Asia Pacific | N/A | N/A | $257M | $242M | $232M | $233M |
| EMEA | $133M | $147M | $367M |
$2.16B
$2.16 Billion
(8.98%)
vs. $2.37B a year ago (TTM)
+11.05%
5 Year compound annual growth rate
1 Year
(8.98%)
3 Year
(1.99%)
5 Year
+11.05%
10 Year
+19.52%
15 Year
+14.05%
20 Year
+12.92%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.23B | ($152.02M) | (6.38%) |
| 2024 | $2.38B | +$122.92M | +5.44% |
| 2023 | $2.26B | ($20.87M) | (0.92%) |
| 2022 | $2.28B | +$963.69M | +73.21% |
| 2021 | $1.32B | +$45.30M | +3.56% |
| 2020 |
TTM Growth
(8.98%)
3-Year CAGR
(1.99%)
5-Year CAGR
+11.05%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T15:12:33.823Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| $75M |
| Government Grant Revenue | N/A | N/A | N/A | N/A | N/A | -$2M |
|---|
| Infusion Consumables | $474M | $555M | $567M | $969M | $1.0B | N/A |
|---|
| Infusion Consumables-Smiths Medical | N/A | N/A | $340M | N/A | N/A | N/A |
|---|
| Infusion Systems | $360M | $352M | $351M | $629M | $652M | N/A |
|---|
| IV Solutions | $389M | $359M | $363M | N/A | N/A | N/A |
|---|
| Other deferred revenue | N/A | N/A | N/A | N/A | N/A | $1M |
|---|
| Software revenue | N/A | N/A | N/A | N/A | N/A | $31M |
|---|
| Vascular Access | N/A | N/A | $327M | N/A | N/A | N/A |
|---|
| Vital Care | N/A | N/A | $285M | $661M | $691M | N/A |
|---|
| $394M |
| $412M |
| Other foreign countries | $228M | $227M | $195M | $204M | $224M | $231M |
|---|
| UNITED STATES | $911M | $942M | $1.5B | $1.4B | $1.5B | $1.4B |
|---|
| $1.27B |
| +$4.80M |
| +0.38% |
| 2019 | $1.27B | ($133.83M) | (9.56%) |
| 2018 | $1.40B | +$107.43M | +8.31% |
| 2017 | $1.29B | +$913.24M | +240.72% |
| 2016 | $379.37M | +$37.70M | +11.04% |
